PreludeDx™ Presents DCIS Precision Medicine Study Results at ASTRO 2021 Annual Meeting

LAGUNA HILLS, Calif.: LAGUNA HILLS, Calif., Oct. 27, 2021 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, presented data in an oral scientific session presentation at the American Society for Radiation Oncology (ASTRO) 63rd Annual Meeting held October 24 – 27,...

Click to view original post